Pro-interleukin-16 is a protein that in humans is encoded by the IL16gene.[1][2] This gene was discovered in 1982 at Boston University by Dr. David Center and Dr. William Cruikshank.[3]
The protein encoded by this gene is a pleiotropic cytokine that functions as a chemoattractant, a modulator of T cell activation, and an inhibitor of HIV replication. The signaling process of this cytokine is mediated by CD4. The product of this gene undergoes proteolytic processing, which is found to yield two functional proteins. The cytokine function is exclusively attributed to the secreted C-terminal peptide, while the N-terminal product may play a role in cell cycle control. Caspase 3 is reported to be involved in the proteolytic processing of this protein. Two alternatively spliced transcript variants encoding distinct isoforms have been reported.[2]
Interleukin 16 (IL-16) is a cytokine that is released by a variety of cells (including lymphocytes and some epithelial cells) that has been characterized as a chemoattractant for certain immune cells expressing the cell surface molecule CD4.
IL-16 was originally described as a factor that could attract activated T cells in humans, it was previously called lymphocyte chemoattractant factor (LCF).[3] Since then, this interleukin has been shown to recruit and activate many other cells expressing the CD4 molecule, including monocytes, eosinophils, and dendritic cells.[4]
The structure of IL-16 was determined following its cloning in 1994.[5] This cytokine is produced as a precursor peptide (pro-IL-16) that requires processing by an enzyme called caspase-3 to become active. CD4 is the cell signalingreceptor for mature IL-16.
↑ 6.06.16.26.36.4Kurschner C, Yuzaki M (1999). "Neuronal interleukin-16 (NIL-16): a dual function PDZ domain protein". J. Neurosci. 19 (18): 7770–80. PMID10479680.
↑ 7.07.1Bannert N, Vollhardt K, Asomuddinov B, Haag M, König H, Norley S, Kurth R (2003). "PDZ Domain-mediated interaction of interleukin-16 precursor proteins with myosin phosphatase targeting subunits". J. Biol. Chem. 278 (43): 42190–9. doi:10.1074/jbc.M306669200. PMID12923170.
Further reading
Wilson KC, Center DM, Cruikshank WW (2005). "The effect of interleukin-16 and its precursor on T lymphocyte activation and growth". Growth Factors. 22 (2): 97–104. doi:10.1080/08977190410001704679. PMID15253385.
Copeland KF (2006). "Modulation of HIV-1 transcription by cytokines and chemokines". Mini Reviews in Medicinal Chemistry. 5 (12): 1093–101. doi:10.2174/138955705774933383. PMID16375755.
Ryan TC, Cruikshank WW, Kornfeld H, et al. (1995). "The CD4-associated tyrosine kinase p56lck is required for lymphocyte chemoattractant factor-induced T lymphocyte migration". J. Biol. Chem. 270 (29): 17081–6. doi:10.1074/jbc.270.29.17081. PMID7615501.
Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID8125298.
Parada NA, Cruikshank WW, Danis HL, et al. (1996). "IL-16- and other CD4 ligand-induced migration is dependent upon protein kinase C". Cell. Immunol. 168 (1): 100–6. doi:10.1006/cimm.1996.0054. PMID8599832.
Bannert N, Baier M, Werner A, Kurth R (1996). "Interleukin-16 or not?". Nature. 381 (6577): 30. doi:10.1038/381030a0. PMID8609984.
Maciaszek JW, Parada NA, Cruikshank WW, et al. (1997). "IL-16 represses HIV-1 promoter activity". J. Immunol. 158 (1): 5–8. PMID8977168.
Laberge S, Ernst P, Ghaffar O, et al. (1997). "Increased expression of interleukin-16 in bronchial mucosa of subjects with atopic asthma". Am. J. Respir. Cell Mol. Biol. 17 (2): 193–202. doi:10.1165/ajrcmb.17.2.2750. PMID9271307.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID9373149.
Zhang Y, Center DM, Wu DM, et al. (1998). "Processing and activation of pro-interleukin-16 by caspase-3". J. Biol. Chem. 273 (2): 1144–9. doi:10.1074/jbc.273.2.1144. PMID9422780.
Mühlhahn P, Zweckstetter M, Georgescu J, et al. (1998). "Structure of interleukin 16 resembles a PDZ domain with an occluded peptide binding site". Nat. Struct. Biol. 5 (8): 682–6. doi:10.1038/1376. PMID9699630.
Chupp GL, Wright EA, Wu D, et al. (1998). "Tissue and T cell distribution of precursor and mature IL-16". J. Immunol. 161 (6): 3114–9. PMID9743378.
Kim HS (1999). "Assignment of human interleukin 16 (IL16) to chromosome 15q26.3 by radiation hybrid mapping". Cytogenet. Cell Genet. 84 (1–2): 93. doi:10.1159/000015224. PMID10343113.
Liu Y, Cruikshank WW, O'Loughlin T, et al. (1999). "Identification of a CD4 domain required for interleukin-16 binding and lymphocyte activation". J. Biol. Chem. 274 (33): 23387–95. doi:10.1074/jbc.274.33.23387. PMID10438516.
Kaser A, Dunzendorfer S, Offner FA, et al. (1999). "A role for IL-16 in the cross-talk between dendritic cells and T cells". J. Immunol. 163 (6): 3232–8. PMID10477592.
Kurschner C, Yuzaki M (1999). "Neuronal interleukin-16 (NIL-16): a dual function PDZ domain protein". J. Neurosci. 19 (18): 7770–80. PMID10479680.